was administered with 5 mg/kg of granulocyte colony-stimulating factor twice a day for five consecutive days under dasatinib therapy. On day 5, the peripheral blood CD34 þ cell concentration was 54.8/mm 3
. Apheresis was carried out using a Cobe Spectra cell separator (Gambro BCT, Stokholm, Sweden), and a cellular product containing 6.86 Â 10 8 nucleated cells/kg, 5.55 Â 10 6 CD34 þ cells/kg and 173.3 Â 10 4 granulocytemacrophage colony-forming unit/kg was harvested and cryopreserved, the bcr-abl/abl IS ratio in the graft being 0.09%. The decision to proceed to an autologous stem cell transplantation was thus taken. Dasatinib treatment ceased at the start of the conditioning regimen consisting of intravenous busulfan and cyclophosphamide. Autologous peripheral blood stem cell transplantation was carried out in January 2006. After thawing, cell viability was 92% and the infused product contained 4.6 Â 10 8 viable nucleated cells/kg and 4.6 Â 10 6 viable CD34 þ cells/kg. Neutrophil and platelet recovery was obtained within 17 days without any granulocyte colony-stimulating factor treatment and no severe documented infection occurred. Dasatinib was not reintroduced. At the last follow-up in June 2008, the patient remained in complete haematological response with a normal karyotype and a stable residual disease measured at 0.01%, in the absence of any tyrosine kinase inhibitor therapy ( Figure 1 ). Gabriel et al. 4 recently reported on one chronic-phase CML patient responding to dasatinib after imatinib resistance, in whom dasatinib combined with granulocyte colony-stimulating factor was effective for peripheral mobilization and collection of CD34 þ cells. Here, we do not only show that we were able to successfully collect and cryopreserve a highquality autologous peripheral blood stem cell graft containing low levels of residual disease under dasatinib, but also show that dasatinib treatment before and during CD34 þ cell mobilization and collection did not impair haematopoietic recovery after transplantation. Finally, the most remarkable finding resides in a stable major molecular response despite the cessation of dasatinib therapy.
We could not investigate on possible mechanisms involved in the maintenance of low residual disease levels in the absence of tyrosine kinase inhibitor therapy in this patient, and we do not widely recommend dasatinib discontinuation at the present time. Nevertheless, our observation suggests that autologous haematopoietic stem cell transplantation in patients responding to dasatinib after imatinib resistance may be a viable therapeutic option for advanced-phase CML patients not eligible for allogeneic transplantation or those lacking a human leukocyte antigen-matched donor. Whether maintenance therapy with dasatinib is required in patients with low levels of residual disease after transplantation should be assessed in the setting of a clinical trial. prognosis is also associated with the inactivation of an important tumor-suppressor p53; these patients harbor a deletion of 17p13 and this chromosomal abnormality is often accompanied by the mutation of the second TP53 allele, which leads to the complete elimination of p53 function. Moreover, a single mutation of one of the TP53 allele also occurs in a significant proportion of CLL cases. Patients with TP53 abnormalities typically do not respond to therapy and have a median survival of less than 3 years. MicroRNAs (miRNAs) are short B22 nucleotide long RNA molecules that function as specific regulators of the gene expression with an essential role in cell proliferation, differentiation, apoptosis, chromosome structure and virus resistance.
These highly conserved RNAs constitute more than 700 miR genes in the human genome and are supposed to regulate 20-30% of protein-coding genes. miRNAs are associated with RNA-induced silencing complex (RISC), which has been previously proven to repress the translation of the mRNA by an RNA interference mechanism. Many studies have shown that miRNAs are aberrantly expressed in cancer cells, suggesting that they might act as a novel class of oncogenes or tumor suppressors. The first evidence of the involvement of miRNAs in chronic lymphocytic leukemia came from molecular studies, which characterized the 13q14 deletion. Two miRNA genes (miR-15a and miR-16-1), which regulate Bcl2, are the candidate genes located in the 13q14.3 region.
1 Several recent publications have defined the miRNA expression profiles in different CLL subtypes: mutated IgV H vs unmutated IgV H and ZAP-70 þ vs ZAP-70À cases. 1 Although, this data did indeed demonstrate the involvement of miRNAs in CLL pathogenesis, their role in aggressive CLL, bearing TP53 abnormalities, has not yet been clearly defined. Therefore, we have focused on the identification of miRNAs abnormally expressed in CLL cells, which harbor a deletion and/or mutation of the p53 gene (TP53).
A cohort of 30 patients from a single institution (University Hospital Brno) was enrolled in this study (del. and/or mut. TP53 n ¼ 12, wild-type (wt) TP53 n ¼ 18; Table 1 ). Standard prognostic markers were determined: IgV H mutation status (with cutoff 98% homology to the germline sequence); p53 functional status by functional yeast assays and fluorescence in situ hybridization (FISH; del13q14, del17p13, del11q23, trisomy 12). Peripheral blood samples were collected; B lymphocytes were separated by the RosetteSep Human B Cell Enrichment antibody cocktail (StemCell Technologies, Vancouver, Canada), and all samples were measured by Flow Cytometry to verify their purity (cutoff was assessed X95% of CD5 þ 19 þ cells).
Total RNA was isolated by TriReagent according to the manufacturer's protocol (MRC, Cincinnati, OH, USA), and capillary electrophoresis (Bioanalyzer RNA 6000 Nano Assay, Agilent, Palo Alto, CA, USA) was performed to validate RNA quality. Real-time PCR (TaqMan miRNA Assays, Applied Biosystems, Foster City, CA, USA) was used to detect the expression of 35 miRNAs (miR-15a, miR-16, miR-17-3p, miR-17-5p, miR-18a, miR-19a, miR-19b, miR-20a, miR-20b, miR-21, miR-23a, miR-23b, miR-24-2, miR-29a, miR-29b, miR-29c, miR-34a, miR-34b, miR-34c, miR-92, miR-142-3p, miR-142-5p, miR-146a, miR-146b, miR-155, miR-181a, miR-181b, miR-181c, miR-181d, miR-195, miR-221, miR-222, miR-223, miR-372, miR-373). These miRNAs were chosen according to literature data and the prediction of potential target mRNA (miRanda, PicTar and TargetsScan). Most of these miRNAs have been frequently discussed in hematopoiesis, lymphocyte development, CLL biology or its clinical subtypes. MicroRNAs expression was also tested in six CD19 þ B lymphocyte control samples obtained from healthy donors after tonsillectomy (separated by RosetteSep Human B Cell Enrichment, purity X99% of CD19 þ cells). The obtained miRNA expression levels were normalized to RNU38B or miR-19b, which are both very uniformly expressed in all B cells samples (tested by geNORM 3.5, CMG, Ghent, the Netherlands). Statistical differences between the miRNA levels were evaluated using the nonparametric Mann-Whitney U-test (Statistica 6.0, StatSoft, Tulsa, OK, USA).
It has already been demonstrated that miRNA miR-16-1 and miR-15a are downregulated in samples with at least one deleted 13q14 allele. 1 In our cohort, miR-16 downregulation was strongly associated with the 13q14 deletion (P ¼ 0.003; monoallelic deletion 13q14 n ¼ 15, undeleted 13q14 n ¼ 15). The expression of miR-15a has also shown such a trend, but with lower statistical significance (P ¼ 0.08). Expression Table 1 Characterization of CLL patients (n ¼ 
TP53 status 17p13 deletion and mutation of TP53 in:
Abbreviations: F, female; FISH, fluorescence in situ hybridization; IgV H , immunoglobulin heavy-chain variable region; M, male.
Letters to the Editor
signatures of the other 33 tested miRNAs were not related to 13q14 status. This data are consistent with previously published results 1 and validates the accuracy of the used real-time PCR method.
We compared an expression of miRNAs in the CLL samples with TP53 abnormalities (n ¼ 12) and wt TP53 samples (n ¼ 18). A significant downregulation of the three miRNAs (miR-34a P ¼ 0.000001; miR-29c P ¼ 0.02; miR-17-5p P ¼ 0.04) was observed (Figures 1a-c) . The most differentially expressed miRNA, miR-34a, was B9-fold downregulated in CLL cells with abnormal TP53 (Figure 1a) . This result was presented by our group at the EHA 2008 meeting (abstract no. 528), and a similar observation has also been very recently reported by two independent studies. 2, 3 Interestingly, three samples, with only the TP53 mutation (no 17p13 deletion), also had low levels of miR-34a and thus behaved similarly to cells with complete TP53 inactivation. Evolutionary conserved miR-34 gene family contains three homologues in humans (miR-34a, miR-34b and miR-34c). The miR-34a is located in the noncoding region B30 kb downstream of the predicted p53-binding site in the 1p36 region, which is frequently deleted in many tumors. Both miR-34b and miR-34c are transcribed as a single precursor molecule from the 11q23 locus, a region of frequent deletion in CLL. Interestingly, we did not detect either an miR-34b or an miR-34c expression in any of our CLL samples (11q23 region was intact according to FISH and aCGH). These two miRNAs were also undetectable in CD19 þ B lymphocytes from the tonsils and the miR-34a expression was low in these control samples. The proof of miR-34 direct regulation by the p53 protein was illustrated by in vitro studies, which identified an induction of its expression in response to DNA damage and oncogenic stress. 4 In the published experiments, miR-34 family members emerged as p53-regulated genes. Microarray analysis showed that the induction of miR-34 leads to the downregulation of hundreds of mRNAs. Several individual genes have been experimentally validated as miR-34 targets including CDK4, CDK6, MYCN, Cyclin E and E2F3. 4 The antiapoptotic BCL2 gene, which is strongly upregulated in the majority of CLL cases and supports the immortality of the B cells, was also reported to be regulated by miR-34. 4 However, Dijkstra et al. has recently reported no difference in the Bcl2 levels between samples with different TP53 status (detected by flow cytometry). 2 Our results also show that cells harboring deletion and/or mutation of the p53 gene have a downregulated expression of miR-29c (Figure 1b , P ¼ 0.02). Recently, it has been reported that the expression of TCL1 and MCL1 (antiapoptotic Bcl2 family member) is regulated by miR-29 in the CLL cells. 5, 6 An enforced miR-29 expression reduced the Mcl-1 protein level, resulting in apoptosis. 5 On the basis of animal models, deregulation of the TCL1 and MCL1 oncogenes was suggested to be an important event in the CLL pathogenesis. The Tcl1 expression has also been shown to be inversely correlated to the frequency of IgV H mutations in humans. 6 Moreover, when we stratified samples with wt TP53 into two categories, according to IgV H status, and compared them with the TP53 abnormal samples, the remaining members of the miR-29 family (miR-29a and miR-29b) showed a higher expression in samples with unmutated IgV H (Figures 2a and b) .
miR-17-5p was the third significantly downregulated miRNA in the samples with abnormal TP53 (Figure 1c , P ¼ 0.04). This miRNA is a part of the c-myc-regulated cluster (miR-17-92) and targets E2F1, p21 and Cyclin D1.
7 miR-17-5p also acts at the G 1 / S-phase cell-cycle checkpoint by targeting genes involved in this transition. The miR-17-5p is able to act both as an oncogene and Figure 1 The expression of miR-34a (a), miR-29c (b) and miR-17-5p (c) in chronic lymphocytic leukemia (CLL) with deleted and/or mutated TP53 gene (del/mut TP53) in comparison with the wild-type TP53 and control CD19 þ B lymphocytes from tonsils. Mean is indicated, boxes represent standard error and bars represent standard deviation. Statistically significant differences are indicated by horizontal lines and P-value. MicroRNAs (miRNAs) expression levels were normalized to RNU38B (miR-34a) and miR-19b (miR-29c and miR-17-5p).
Letters to the Editor a tumor suppressor by regulating pro-and antiproliferative genes in different cellular contexts. Moreover, miR-17-92 is included in the c-myc-mediated repression of hypoxia-inducible factor1a (HIF-1a). 8 HIF-1a plays a role in cell proliferation during hypoxia, and its upregulation in CLL bone marrow biopsies was linked with microvessel proliferation. Interestingly, other hypoxia-associated miRNA family miR-23 has a higher expression in the unmutated IgV H samples (Figures 2c and d) .
In addition, we have performed the analysis of miRNAs expression in unmutated (n ¼ 17) and mutated (n ¼ 12) IgV H samples (irrespective of the TP53 status). We have observed miR-23a and miR-15a downregulation in the mutated IgV H samples; downregulation of other two miRNAs (miR-23b and miR-142-3p) was significant after exclusion of TP53 abnormal samples (Pp0.05). Interestingly, miR-16 expression pattern was dissimilar to the miR15a, even though this miRNA is closely co-localized and related to the miR-15a (13q14 cluster). The obtained expression values for all studied miRNAs and CLL samples are presented in Figure 3 .
To summarize, our results indicate that miRNAs expression signatures are closely associated to the biological subtypes of CLL. Our study is the first to document the deregulated miR expression pattern (miR-34a, miR-29 and miR-17-5p) in patients with deleted and/or mutated p53 gene. These miRNAs target genes, which were previously proposed to be involved in CLL pathogenesis including BCL2, TCL1, MCL1 and also cell-cycle (E2F1, p21, Cyclin D1) and hypoxia-related genes (HIF-1a). Further analysis is required to define the exact role of these miRNAs in target genes deregulation and hence their biological role in pathogenesis or potential prognostic relevance in CLL patients. 
